Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Ardelyx, Inc.NASDAQ: ARDX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $14.16M rose 17.1% year over year, behind the +21.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 13.8% from the prior quarter. Over 3 fiscal years it compounded at +65.8% a year.

Context

  • Stock-based compensation amounted to 12.0% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.1% toward the trailing-twelve-month pace of +21.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.16M+13.8% QoQ
Last fiscal yearDec 2025
$48.96M+31.0% YoY
LTMMar 2026
$51.03M+21.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.1%——
1 year+31.0%——
3-year CAGR+65.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
48.96M USD
Year-over-year change
+31.0%
4-year CAGR
+42.0%

Stock-Based Compensation vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 stock-based compensation of $51.03M is the largest of the 5 companies compared; the peer median is $16.52M.
  • Its year-over-year change of +21.9% is the 3rd highest of 5, against a peer median of +41.9%.
  • Stock-based compensation amounts to 11.9% of revenue for ARDX, versus a peer median of 7.0%.
ARDX Competitors Peer median
Stock-Based Compensation for ARDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$51.03M +21.9%+65.8%11.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$22.06M +15.9%+22.5%7.0%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20.28M +92.0%+34.5%101.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$12.76M +67.9%-14.2%5.5%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$2.79M +13.0%+36.8%—
Peer median (excluding ARDX) $16.52M+41.9%+28.5%7.0%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Depreciation & Amortization1.44M1.14M1.29M2.06M3.06M
Deferred Income Tax(190K)0000
Stock-Based Compensation12.04M10.75M13.53M37.38M48.96M
Change in Working Capital(11.92M)(19.58M)(43.39M)(49.17M)(31.35M)
Accounts Receivables(502K)(7.23M)(14.3M)(35.67M)(14.14M)
Inventory(10.37M)(28.35M)(21.14M)(41.7M)(31.92M)
Accounts Payables(1.35M)6.58M279K4.86M3.24M
Other Working Capital300K9.42M(8.23M)23.34M11.48M
Other Non-Cash Items4.25M4.84M4.91M4.05M(1.55M)
Operating Cash Flow(152.55M)(70.04M)(89.72M)(44.81M)(42.48M)
Capital Expenditures(1.87M)(55K)(344K)(1.01M)(1.49M)
Acquisitions (Net)(52.82M)0000
Purchases of Investments(72.74M)(50.33M)(215.23M)(195.16M)(218.92M)
Sales of Investments125.55M67M84.32M177.85M211.46M
Other Investing Activities52.82M1.8M000
Investing Cash Flow50.95M18.42M(131.25M)(18.32M)(8.96M)
Debt Repayment(19.44M)(6.07M)22.39M99.45M48.67M
Common Stock Issued101.15M71.63M119.24M8.14M5.84M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.3M9.78M4.67M(1M)0
Financing Cash Flow83M75.34M146.3M106.59M54.51M
Effect of Forex Changes00000
Net Change in Cash(18.6M)23.71M(74.67M)43.46M3.07M
Free Cash Flow(154.42M)(70.1M)(90.06M)(45.82M)(43.98M)

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.